パートナー
多岐に渡る知的財産法分野で経験を有する。米国地方裁判所訴訟及び控訴審を中心に、膨大な数の米国特許案件をリード・カウンセルとして手掛ける。中でも、医薬品の承認を規定するハッチ・ワックスマン法をめぐる訴訟経験が豊富。
Jトレード・ドレス、不正競争、独占禁止法問題でも代理人を務める。裁判所、仲介者、及び調停人の前で代理人として手腕を発揮。また、国内外のクライアントに対し、侵害、有効性、執行可能性及びクリアランス、等米国知財法に関する意見書を提供しカウンセリングを行い、ライセンス、独占禁止法、デュー・デリジェンス、知的財産ポートフォリオ問題で助言する。米国特許法と医療品及び医療機器の販売に関する米国食品医薬品局(FDA)の承認取得過程の相互関係についても助言する。
製薬、化学、バイオテクノロジー、及び機械技術を中心に多岐に渡る技術分野を手掛ける。代理するクライアントの産業分野は幅広く、医薬品、工業用化学品、飲料組成物、食品、梱包材、光化学、石油精製、バイオ燃料、合金、紙製品、ガラス製造、及び医療機器に渡る。
ハッチ・ワックスマン法問題を中心に、米国知的財産保護に関する講義を多数行う。非常勤講師として特許訴訟分野の授業も手掛ける。あらゆる業界紙で一流の特許訴訟弁護士としてその業績が評価され、Intellectual Asset Management 誌、LMG Life Sciences誌、 The Legal 500 U.S誌では特許ポートフォリオ管理とライセンシング部門で高い評価を得ている。
弊所の経営委員会メンバー。これまで、マネージングパートナー、チェア、化学プラクティスグループリーダー、リクルーティングパートナーを務める。
Otsuka Pharmaceutical Co., Ltd. v. Sandoz, Inc.
Lead counsel for Otsuka at trial and on appeal in Hatch-Waxman litigations against several companies seeking to market generic copies of Abilify®, which had sales of over $5.2 billion in 2011 alone. Following a month-long trial, district court ruled in favor of Otsuka on all issues, Federal Circuit affirmed, and Supreme Court denied cert, thus maintaining patent and regulatory protection for Abilify® in the United States from 2010-2015.
3:07-cv-01000, D.N.J., Judges Cooper, Goodman, Hughes
11-1126, -1127, Fed. Cir., Judges Lourie, Moore, Reyna
Horizon Pharma v. Dr. Reddy's Laboratories, et al.
Lead counsel for Horizon in Hatch-Waxman patent infringement litigations against several companies seeking to market generic copies of Vimovo®. District court ruled in favor of Horizon, and appeal now pending.
3:11-cv-02317, 3:11-cv-04275, 3:13-cv-00091, 3:13-cv-04022, D.N.J., Judge Cooper
17-2473, -2481, -2484, -2486, -2487, -2488, -2489, -2491, -2491, -2493, Fed. Cir.
Elan Corporation PLC v. Andrx Pharmaceutical
Lead counsel for Elan at trial and on appeal in Hatch-Waxman litigation involving Andrx’s efforts to market generic copies of Naprelan®. District court found in favor of Elan on all issues, including a finding of willful infringement, and the parties ultimately settled an at-risk launch damages case in a confidential settlement involving significant payments to Elan.
0:98-cv-07164; 0:00-cv-07057; 0:05-cv-60158, S.D. Fla., Judge Jordan
03-1354, -1355, -1386, -1387, Fed. Cir., Judges Michel, Lourie, Dyk
Pronova Biopharma Norge AS v. Teva Pharmaceuticals USA, Inc.
Lead counsel for Pronova at trial and on appeal in Hatch-Waxman patent litigation against three companies seeking to market generic versions of Lovaza®. District court found in favor of Pronova on all issues, including patent infringement, validity, and enforceability.
1:09-cv-00286, 1:10-cv-00800, D. Del., Judges Farnan, Robinson, Thynge
12-1498, -1499, Fed. Cir., Judges Dyk, O'Malley, Wallach
Classen Immunotherapies, Inc. v. Elan Pharmaceuticals, Inc.
Lead counsel in defending Elan at district court and in two appeals with respect to Classen’s infringement allegations regarding Elan’s Skelaxin® portfolio. District court granted summary judgment of non-infringement in favor of Elan. Federal Circuit affirmed, and Supreme Court denied cert. Also successfully represented Elan in related reexamination proceedings before the U.S. Patent and Trademark Office (USPTO).
1:04-cv-03521, D. Md., Judges Bennett, Quarles, Sullivan
14-1671, Fed. Cir., Judges Prost, Lourie, Gilstrap
17-1033, Fed. Cir., Judges Prost, Lourie, Taranto
Aventis Pharma, S.A. v. Baxter Healthcare Corp.
Represented Aventis in patent infringement action asserting infringement against Baxter’s Advate® product for treating hemophilia. Case successfully resolved through a confidential arbitration trial, resulting in award to Aventis of the highest damages amount available under parties’ arbitration agreement.
1:06-cv-00636, D. Del., Judge Sleet
Event
Finnegan Tokyo Office 30th Anniversary Seminar & Reception Finnegan Tokyo Office 30th Anniversary Seminar & Reception
October 18, 2018
Tokyo
Articles
Trusted Advisor Interview: The Power of Collaboration Trusted Advisor Interview: The Power of Collaboration
September 25, 2017
Event
Seminar on Issues of Intellectual Property Seminar on Issues of Intellectual Property
October 10-15, 2014
Washington
Seminar
Strategies for a Changing IP Landscape Strategies for a Changing IP Landscape
February 26, 2014
London
Articles
Obviousness of DNA Fragments in the Post-Kubin Era Obviousness of DNA Fragments in the Post-Kubin Era
April 30, 2013
Life Sciences Intellectual Property Review"Monroe is hard to compete with when it comes to Hatch-Waxman litigation."
Intellectual Asset Management Patent 1000
"Monroe is hard to compete with when it comes to Hatch-Waxman litigation."
Intellectual Asset Management Patent 1000
Award/Ranking
Finnegan Receives Tier 1 Benchmark Litigation Rankings; Nine Attorneys Named Litigation Stars Finnegan Receives Tier 1 Benchmark Litigation Rankings; Nine Attorneys Named Litigation Stars
October 5, 2023
Benchmark LitigationAward/Ranking
Finnegan Upholds Tier 1 Marks in 2023 LMG Life Sciences Rankings Finnegan Upholds Tier 1 Marks in 2023 LMG Life Sciences Rankings
September 21, 2023
LMG Life SciencesPress Release
Finnegan Takes Home Three Wins at the 2023 LMG Life Sciences Americas Awards Finnegan Takes Home Three Wins at the 2023 LMG Life Sciences Americas Awards
September 8, 2023
LMG Life SciencesAward/Ranking
Finnegan Shortlisted in 10 Categories in the LMG Life Sciences Awards 2023 Finnegan Shortlisted in 10 Categories in the LMG Life Sciences Awards 2023
July 25, 2023
LMG Life SciencesPress Release
Managing Intellectual Property IP Stars: Finnegan Scores Top Patent Rankings Across the Board Managing Intellectual Property IP Stars: Finnegan Scores Top Patent Rankings Across the Board
July 13, 2023
Managing Intellectual PropertyPress Release
Finnegan Receives Top Rankings from Intellectual Asset Management; 46 Attorneys Ranked Finnegan Receives Top Rankings from Intellectual Asset Management; 46 Attorneys Ranked
June 30, 2023
Intellectual Asset ManagementDue to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.